equitydrlalpathresults

Dr. Lal Path Lab, Results Analysis-Q1FY27

Profile picture of Rakesh Kumar Singhal
Rakesh Kumar Singhal · INH10000328219 Aug 2026 · 1 min read · Updated 19 Aug 2026, 11:05 am

Financial performance and key operating metrics (consolidated)

Operating Revenue for Q1FY27 is Rs. 798 Crs., 19.1% growth YoY (“highest quarterly growth rate achieved in the last four years), Total Income is Rs. 830 Crs., 18.87% growth YoY, Gross Profit is Rs. 530 Crs., 19.12% growth YoY, EBITDA is Rs. 248 Crs., 28.71% growth YoY, EBITDA Margin is 31.03% improved by 232 basis points YoY, PBT Rs. 229 Crs., 26.28% growth YoY, PAT Rs. 171 Crs. 27.24% growth YoY.

 

On QoQ basis Op. Revenue is up by 13.52%, Total Income is up by 14.16%, Gross Profit is up by 13.56%, EBITDA is up by 32.49%, EBITDA Margin also improved by 444 BPS, PBT is up by 42.85% and PAT is also up by 28.97%.

Patient volumes: 8.2 million, +8.2% YoY, Sample volumes: 25.9 million, +10.7% YoY.

 

New launches: 116 new tests in the quarter, including 4 “first in India” tests.

 

CGHS/ECHS price revisions are now “flowing through into the system.”

 

Hospitals capacity expansion enabling “stronger clinical partnerships” and “great scope for super specialized testing over time.”

Indian Healthcare Services is a large and growing opportunity